Renal expression of proto-oncogene Ets-1 on matrix remodeling in experimental diabetic nephropathy

Acta Histochemica

Volumn 113, Issue 5, 2011, Pages 527-533

  Liu, Dian xin ^a   Liu, Xiao min ^a   Su, Ying ^a   Zhang, Xiao juan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Ets 1; Metalloproteinase 2; Rat; Tissue inhibitor of metalloproteinase 2; Type IV collagen

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 4; GELATINASE A; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR ETS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; NONHUMAN; PATHOGENESIS; PROTO ONCOGENE; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES;

ACTINS; ANIMALS; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; GLOMERULAR BASEMENT MEMBRANE; GLOMERULAR MESANGIUM; KIDNEY; MALE; MATRIX METALLOPROTEINASE 2; PROTO-ONCOGENE PROTEIN C-ETS-1; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

RATTUS;

EID: 79955479259     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2010.05.006     Document Type: Article

References (28)

1. Campbell R.K., Neumiller J.J., White J., Sisson E., Kuhn C. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist. J Am Pharm Assoc 2009, 49(Suppl 1):2.
2. Catania J.M., Chen G., Parris A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007, 292:905-911.
3. Chen S., Pollock A.S., Mahimkar R., Olson J.L., Lovett D.H. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006, 20:1898-1900.
4. Iwasaka C., Tanaka K., Abe M., Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996, 169:522-531.
5. Lenz O., Elliot S.J., Stetler-Stevenson W.G. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 2000, 11:574-581.
6. Liu D., Razzaque M.S., Cheng M., Taguchi T. The renal expression of heat shock protein 47 and collagens in acute and chronic experimental diabetes in rats. J Histochem 2001, 33:621-628.
7. Liu D., Razzaque M.S., Nazneen A., Naito T., Taguchi T. Role of heat shock protein 47 on tubulointerstitium in experimental radiation nephropathy. Pathol Int 2002, 52:340-347.
8. Liu D., Nazneen A., Taguchi T., Razzaque M.S. Low-dose local kidney irradiation inhibits progression of experimental crescentic nephritis by promoting apoptosis. Am J Nephrol 2008, 28:555-568.
9. Liu D.G., Wang T.M. Role of connective tissue growth factor in experimental radiation nephropathy in rats. J Chin Med (Engl) 2008, 121:1925-1931.
10. Mankhey R.W., Wells C.C., Bhatti F., Maric C. 17 beta-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 2007, 292:769-777.
11. McMillan J.I., Riordan J.W., Couser W.G., Pollock A.S., Lovett D.H. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996, 97:1094-1101.
12. Mizui M., Isaka Y., Takabatake Y., Sato Y., Kawachi H., Shimizu F., et al. Transcription factor Ets-1 is essential for mesangial matrix remodeling. Kidney Int 2006, 70:298-305.
13. Naito T., Razzaque M.S., Nazneen A., Liu D., Nihei H., Koji T., et al. Renal expression of the Ets-1 proto-oncogene during progression of rat crescentic glomerulonephritis. J Am Soc Nephrol 2000, 11:2243-2255.
14. Nazneen A., Razzaque M.S., Liu D., Taguchi T. Possible role of Ets-1 and MMP-1 in matrix remodeling in experimental cisplatin nephropathy. Med Electron Microsc 2002, 35:242-247.
15. Nunn M.F., Seeburg P.H., Moscovici C., Duesberg P.H. Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature 1983, 306:391-395.
16. Okuducu A.F., Zils U., Michaelis S.A., Michaelides S., von Deimling A. Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology 2006, 48:836-845.
17. Pearse D.D., Tian R.X., Nigro J., Iorgulescu J.B., Puzis L., Jaimes E.A. Angiotensin II increases the expression of the transcription factor Ets-1 in mesangial cells. Am J Physiol Renal Physiol 2008, 294:1094-1100.
18. Portik-Dobos V., Harris A.K., Song W., Hutchinson J., Johnson M.H., Imig J.D., et al. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol 2006, 290:435-441.
19. Raffetseder U., Wernert N., Ostendorf T., van Roeyen C., Rauen T., Behrens P., et al. Mesangial cell expression of proto-oncogene Ets-1 during progression of mesangioproliferative glomerulonephritis. Kidney Int 2004, 66:622-632.
20. Reisdorff J., En-Nia A., Stefanidis I., Floege J., Lovett D.H., Mertens P.R. Transcription factor Ets-1 regulates gelatinase A gene expression in mesangial cells. J Am Soc Nephrol 2002, 13:1568-1578.
21. Rodriguez W.E., Tyagi N., Joshua I.G., Passmore J.C., Fleming J.T., Falcone J.C., et al. Pioglitazone mitigates renal glomerular vascular changes in high-fat high calorie induced type 2 diabetes mellitus. Am J Physiol Renal Physiol 2006, 291:694-701.
22. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003, 200:448-464.
23. Sun S.Z., Wang Y., Li Q., Tian Y.J., Liu M.H., Yu Y.H. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. J Chin Med (Engl) 2006, 119:814-821.
24. Tuncdemir M., Ozturk M. The effects of ACE inhibitor and angiotensin receptor blocker on clusterin and apoptosis in the kidney tissue of streptozotocin-diabetic rats. J Mol Histol 2008, 39:605-616.
25. Wenzel R.R., Littke T., Kuranoff S., Jürgens C., Bruck H., Ritz E., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009, 20:655-664.
26. Wörnle M., Roeder M., Sauter M., Ribeiro A. Role of matrix metalloproteinases in viral-associated glomerulonephritis. Nephrol Dial Transplant 2009, 24:1113-1121.
27. Wu K., Setty S., Mauer S.M., Killen P., Nagase H., Michael A.F., et al. Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anat (Basel) 1997, 158:155-165.
28. Zhou M.S., Hernandez Schulman I., Pagano P.J., Jaimes E.A., Raij L. Reduced NAD (P) H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 2006, 47:81-86.